Tozer Tiffany, MacKenzie Meghan, Burgess Sarah, Loubani Osama, Neville Heather
, BSc (Pharm), ACPR, is with the Pharmacy Department, Nova Scotia Health, Halifax, Nova Scotia.
, BSc(Pharm), ACPR, PharmD, is with the Pharmacy Department, Nova Scotia Health, and the College of Pharmacy, Dalhousie University, Halifax, Nova Scotia.
Can J Hosp Pharm. 2023 Jan 9;76(1):29-39. doi: 10.4212/cjhp.3245. eCollection 2023 Winter.
Opioid misuse constitutes a health care crisis in Canada, and coprescription of opioids with sedatives has been associated with adverse events. Opioids and sedatives are frequently administered in the intensive care unit (ICU). The rate of continuation of opioid-sedative combinations after an ICU admission at the study institution was unknown.
To determine the rates of opioid and sedative coprescriptions following an ICU admission and to identify factors associated with continuation of hospital-initiated opioid-sedative coprescriptions at ICU transfer and hospital discharge.
This retrospective chart review involved patients admitted to ICUs at a tertiary care centre between April 1, 2018, and March 31, 2019. Baseline characteristics were obtained from a clinical database and medication information from medication reconciliation forms. An opioid coprescription was defined as prescription of an opioid in combination with a sedative (benzodiazepine, z-drug, gabapentinoid, tricyclic antidepressant, or antipsychotic), and hospital-initiated coprescriptions encompassed various predefined scenarios of therapy started or modified before ICU transfer. Factors associated with hospital-initiated opioid coprescription were analyzed by multivariable logistic regression.
A total of 735 patients met the inclusion criteria. At ICU transfer, 23.0% (169/735) of the patients had an opioid coprescription, and 87.0% (147/169) of these coprescriptions were hospital-initiated. At hospital discharge, 8.6% (44/514) of the patients had an opioid coprescription, and 56.8% (25/44) of these coprescriptions were hospital-initiated. Male sex, home opioid coprescription, surgical patient, prolonged hospital stay, and in-hospital death were significantly associated with hospital-initiated opioid coprescription at the time of ICU transfer. Home opioid coprescription was significantly associated with opioid coprescription at the time of hospital discharge.
Hospital-initiated opioid coprescriptions accounted for the majority of opioid coprescriptions at ICU transfer and hospital discharge. Pharmacists should assess all opioid coprescriptions to determine whether discontinuation and/or dose reduction is appropriate.
阿片类药物滥用在加拿大构成了一场医疗危机,阿片类药物与镇静剂的联合处方与不良事件相关。阿片类药物和镇静剂常在重症监护病房(ICU)使用。在研究机构,ICU入院后阿片类药物与镇静剂联合用药的持续率尚不清楚。
确定ICU入院后阿片类药物和镇静剂联合处方的比例,并确定与ICU转出及出院时医院起始的阿片类药物与镇静剂联合处方持续使用相关的因素。
这项回顾性病历审查涉及2018年4月1日至2019年3月31日期间在一家三级护理中心ICU住院的患者。基线特征从临床数据库中获取,用药信息从用药核对表中获取。阿片类药物联合处方定义为阿片类药物与镇静剂(苯二氮䓬类、Z类药物、加巴喷丁类、三环类抗抑郁药或抗精神病药)联合处方,医院起始的联合处方包括在ICU转出前开始或调整的各种预定义治疗方案。通过多变量逻辑回归分析与医院起始的阿片类药物联合处方相关的因素。
共有735名患者符合纳入标准。在ICU转出时,23.0%(169/735)的患者有阿片类药物联合处方,其中87.0%(147/169)的联合处方是医院起始的。在出院时,8.6%(44/514)的患者有阿片类药物联合处方,其中56.8%(25/44)的联合处方是医院起始的。男性、家庭阿片类药物联合处方、外科手术患者、住院时间延长和院内死亡与ICU转出时医院起始的阿片类药物联合处方显著相关。家庭阿片类药物联合处方与出院时的阿片类药物联合处方显著相关。
在ICU转出和出院时,医院起始的阿片类药物联合处方占阿片类药物联合处方的大多数。药剂师应评估所有阿片类药物联合处方,以确定是否适合停药和/或减量。